-- TransThera Sciences (Nanjing) (HKG:2617) completed the placing of nearly 5.1 million shares to at least six investors at a net issue price of HK$55.49 apiece to raise net proceeds HK$282.2 million, according to a Tuesday Hong Kong bourse filing.
The shares represent 1.65% of the clinical-stage biopharmaceutical firm's issued Hong Kong-listed shares and 1.26% of its total issued share capital as enlarged by the placing.
The firm will use proceeds for research and development, the manufacturing and commercialization of core product Tinengotinib in China, and working capital and general corporate purposes.